MET and non-small cell lung carcinoma: Though there are no approved targeted therapies for NSCLC patients with MET amplifications, this alteration has been recognized as an emerging biomarker due to evidence of clinical activity against MET-amplified tumors with TKIs approved for MET exon 14 skipping mutations (13).